期刊文献+

SST中间神经元功能降低对抑郁症的影响

Effect of Somatostatin-Expressing Interneuron Deficits in Depression
下载PDF
导出
摘要 抑郁症(major depressive disorder)是一种常见的精神疾病,但其病理机制尚不清楚。近年来,研究发现神经网络的兴奋与抑制平衡失调可能是导致抑郁症的重要因素之一,该平衡主要由兴奋性谷氨酸能锥体神经元(pyramidal neuron)和抑制性γ-氨基丁酸(GABA)神经元协调完成。SST中间神经元是主要的抑制神经元,调节锥体神经元活动,参与应激反应,对应激有较高的易感性,在抑郁症患者背腹侧前额叶(dlPFC)、扣带回(ACC)、海马等脑区皆发现了SST mRNA或蛋白水平降低。本文将综述SST中间神经元功能及其功能降低对抑郁症影响的研究结果,包括在不同脑区(如前额叶、海马等)的表现、起因、相关的抑郁症药物研发。 Major depressive disorder is a common mental illness, but its pathological mechanism is still unclear. In recent years, studies have found that imbalance of neural network excitability and inhibition may be one of the important factors leading to depression, which is mainly caused by the incoordination between excitatory glutamatergic pyramidal neurons and inhibitory gamma-aminobutyric acid neurons. Somatostatin-expressing interneurons, the main inhibitory neurons, regulate pyramidal neuronal activity, participate in stress response, and have a high susceptibility to stress. In the dorsal ventral frontal lobes (dlPFC), cingulate gyrus (ACC), hippocampus and other brain regions in patients with depression, researchers have found a decrease in SST mRNA and protein levels. This article will review the function of somatostatin-expressing interneuron and how its functional reduction impacts depression, including causes and performance.
作者 郭沉
出处 《心理学进展》 2019年第10期1767-1777,共11页 Advances in Psychology
  • 相关文献

参考文献1

二级参考文献126

  • 1Kessler RC, Bromet EJ. The epidemiology of depression across cultures. Annu Rev Public Health 2013, 34: 119-138.
  • 2Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et aL The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003, 289: 3095-3105.
  • 3Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med 2001,7: 541-547.
  • 4Belmaker RH, Agam G. Major depressive disorder. N Engl J Med 2008, 358: 55-68.
  • 5Rush A J, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR* D report. Am J Psychiatry 2006, 163: 1905- 1917.
  • 6Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci 2006, 7: 137-151.
  • 7Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J; Diazgranados N, Cravchik A, et al. Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 2012, 71: 939-946.
  • 8Berman RM, Cappiello A, Anand A, Oren DA, Heninger GF Charney DS, et al. Antidepressant effects of ketamine depressed patients. Biol Psychiatry 2000, 47: 351-354.
  • 9Hirschfeld RM. History and evolution of the monoamine hypothesis of depression. J Clin Psychiatry 2000, 61 Suppl 6: 4-6.
  • 10Hanson ND, Owens M J, Nemeroff CB. Depression, antidepressants, and neurogenesis: a critical reappraisal. Neuropsychopharmacology 2011,36: 2589-2602.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部